Cargando…

Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate

Treatment of active, moderate-to-severe Graves’ orbitopathy (GO) is the administration of intravenous methylprednisolone (IVMP). IVMP may be followed by additional therapy with oral prednisone. The aim of this study was to analyze the impact of IVMP on adrenal function by evaluation of serum, saliva...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelewicz, Katarzyna, Szewczyk, Sebastian, Miśkiewicz, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601692/
https://www.ncbi.nlm.nih.gov/pubmed/33050327
http://dx.doi.org/10.3390/jcm9103233
_version_ 1783603490295119872
author Pelewicz, Katarzyna
Szewczyk, Sebastian
Miśkiewicz, Piotr
author_facet Pelewicz, Katarzyna
Szewczyk, Sebastian
Miśkiewicz, Piotr
author_sort Pelewicz, Katarzyna
collection PubMed
description Treatment of active, moderate-to-severe Graves’ orbitopathy (GO) is the administration of intravenous methylprednisolone (IVMP). IVMP may be followed by additional therapy with oral prednisone. The aim of this study was to analyze the impact of IVMP on adrenal function by evaluation of serum, salivary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S). Fourteen patients received IVMP treatment (cumulative dose of 4.5 g in 12 weekly infusions) followed by oral prednisone (for three months). All patients showed normal adrenal function before the 12th IVMP pulse and one patient was diagnosed with secondary adrenal insufficiency (AI) after prednisone treatment. DHEA-S was significantly lower before the 12th IVMP pulse and after oral prednisone (p = 0.015 and p = 0.00002, respectively) in comparison to evaluation before therapy. DHEA-S levels were below the reference range in one and three patients before the 12th IVMP pulse and after prednisone therapy, respectively. We observed decreased serum (p = 0.05) and salivary (p = 0.011) cortisol levels after oral prednisone therapy in comparison to evaluation before therapy. Treatment with IVMP in a cumulative dose of 4.5 g affects adrenal function, causing more severe impairment of DHEA-S secretion than that of cortisol but does not cause secondary AI. Additional therapy with oral glucocorticoids after IVMP can cause secondary AI.
format Online
Article
Text
id pubmed-7601692
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76016922020-11-01 Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate Pelewicz, Katarzyna Szewczyk, Sebastian Miśkiewicz, Piotr J Clin Med Article Treatment of active, moderate-to-severe Graves’ orbitopathy (GO) is the administration of intravenous methylprednisolone (IVMP). IVMP may be followed by additional therapy with oral prednisone. The aim of this study was to analyze the impact of IVMP on adrenal function by evaluation of serum, salivary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S). Fourteen patients received IVMP treatment (cumulative dose of 4.5 g in 12 weekly infusions) followed by oral prednisone (for three months). All patients showed normal adrenal function before the 12th IVMP pulse and one patient was diagnosed with secondary adrenal insufficiency (AI) after prednisone treatment. DHEA-S was significantly lower before the 12th IVMP pulse and after oral prednisone (p = 0.015 and p = 0.00002, respectively) in comparison to evaluation before therapy. DHEA-S levels were below the reference range in one and three patients before the 12th IVMP pulse and after prednisone therapy, respectively. We observed decreased serum (p = 0.05) and salivary (p = 0.011) cortisol levels after oral prednisone therapy in comparison to evaluation before therapy. Treatment with IVMP in a cumulative dose of 4.5 g affects adrenal function, causing more severe impairment of DHEA-S secretion than that of cortisol but does not cause secondary AI. Additional therapy with oral glucocorticoids after IVMP can cause secondary AI. MDPI 2020-10-09 /pmc/articles/PMC7601692/ /pubmed/33050327 http://dx.doi.org/10.3390/jcm9103233 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pelewicz, Katarzyna
Szewczyk, Sebastian
Miśkiewicz, Piotr
Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title_full Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title_fullStr Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title_full_unstemmed Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title_short Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
title_sort treatment with intravenous methylprednisolone in patients with graves’ orbitopathy significantly affects adrenal function: assessment of serum, salivary cortisol and serum dehydroepiandrosterone sulfate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601692/
https://www.ncbi.nlm.nih.gov/pubmed/33050327
http://dx.doi.org/10.3390/jcm9103233
work_keys_str_mv AT pelewiczkatarzyna treatmentwithintravenousmethylprednisoloneinpatientswithgravesorbitopathysignificantlyaffectsadrenalfunctionassessmentofserumsalivarycortisolandserumdehydroepiandrosteronesulfate
AT szewczyksebastian treatmentwithintravenousmethylprednisoloneinpatientswithgravesorbitopathysignificantlyaffectsadrenalfunctionassessmentofserumsalivarycortisolandserumdehydroepiandrosteronesulfate
AT miskiewiczpiotr treatmentwithintravenousmethylprednisoloneinpatientswithgravesorbitopathysignificantlyaffectsadrenalfunctionassessmentofserumsalivarycortisolandserumdehydroepiandrosteronesulfate